Investors should anticipate near-term dilution from the stock offering and potential future dilution from the convertible notes. The concurrent nature of these capital raises suggests the company is strengthening its balance sheet but at the cost of shareholder value. Monitor the use of proceeds and whether the note offering is completed.
Price Chart
Executive Summary
Revolution Medicines is conducting a $750 million common stock offering and a concurrent $250 million convertible note offering. The stock offering will dilute existing shareholders and increase capital, while the convertible notes add leverage and potential future dilution upon conversion.
Key Facts
- Revolution Medicines is offering $750 million of common stock
- Concurrently offering $250 million aggregate principal amount of convertible senior notes due 2033
- The two offerings are not contingent on each other's completion
- Stock offering will result in immediate dilution to new investors
- Convertible notes could lead to future dilution upon conversion
Financial Impact
The company will receive approximately $750 million from the stock offering and $250 million from the convertible notes, less underwriting discounts and expenses
Risk Factors
- Significant dilution to existing shareholders from the stock offering
- Future dilution potential from convertible notes
- Increased leverage from the debt offering
- Market may react negatively to the dilutive capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-152978 |
| Document: 0001193125-26-152978-index-headers.html | 0001193125-26-152978 |
| Document: 0001193125-26-152978-index.html | 0001193125-26-152978 |
| Document: 0001193125-26-152978.txt | 0001193125-26-152978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 17, 2026 24w ago | 8-K | $1.88 $9.07 | ▼ −382.45% | ▼ −375.67% | — |
Apr 16, 2026 24w ago | 8-K | $1.88 $8.98 | ▲ +377.66% | ▲ +371.52% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▲ +376.60% | ▲ +369.55% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 15, 2026 24w ago | 144 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 8-K | $1.88 $9.66 | ▲ +413.83% | ▲ +404.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access